Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

N.S. Stuart; G. von Minckwitz; I. Chernozemsky; L. Sirakova; P. Chilingirov; R. Souchon; N. Marschner; U. Kleeberg; C. Tsekov; D. Fritze; C.F. Thomssen; N. Stuart; J.B. Vermorken; S. Loibl; K.H. Merkle; M. Kaufmann

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

N.S. Stuart
, G. von Minckwitz
, I. Chernozemsky
, L. Sirakova
, P. Chilingirov
, R. Souchon
, N. Marschner
, U. Kleeberg
, C. Tsekov
, D. Fritze
, C.F. Thomssen
, N. Stuart
, J.B. Vermorken
, S. Loibl
, K.H. Merkle
, M. Kaufmann

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

Iaith wreiddiol	Saesneg
Tudalennau (o-i)	871-877
Cyfnodolyn	Anti-Cancer Drugs
Cyfrol	16
Rhif cyhoeddi	8
Statws	Cyhoeddwyd - 1 Medi 2005

NDC y CU

Mae’r allbwn hwn yn cyfrannu at y Nod(au) Datblygu Cynaliadwy canlynol

Dyfynnu hyn

Stuart, N. S., von Minckwitz, G., Chernozemsky, I., Sirakova, L., Chilingirov, P., Souchon, R., Marschner, N., Kleeberg, U., Tsekov, C., Fritze, D., Thomssen, C. F., Stuart, N., Vermorken, J. B., Loibl, S., Merkle, K. H., & Kaufmann, M. (2005). Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs, 16(8), 871-877.

Stuart, N.S. ; von Minckwitz, G. ; Chernozemsky, I. et al. / Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Yn: Anti-Cancer Drugs. 2005 ; Cyfrol 16, Rhif 8. tt. 871-877.

@article{7237d35175a848c7815010de6a05146f,

title = "Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC",

author = "N.S. Stuart and \{von Minckwitz\}, G. and I. Chernozemsky and L. Sirakova and P. Chilingirov and R. Souchon and N. Marschner and U. Kleeberg and C. Tsekov and D. Fritze and C.F. Thomssen and N. Stuart and J.B. Vermorken and S. Loibl and K.H. Merkle and M. Kaufmann",

year = "2005",

month = sep,

day = "1",

language = "English",

volume = "16",

pages = "871--877",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Stuart, NS, von Minckwitz, G, Chernozemsky, I, Sirakova, L, Chilingirov, P, Souchon, R, Marschner, N, Kleeberg, U, Tsekov, C, Fritze, D, Thomssen, CF, Stuart, N, Vermorken, JB, Loibl, S, Merkle, KH & Kaufmann, M 2005, 'Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC', Anti-Cancer Drugs, cyfrol. 16, rhif 8, tt. 871-877.

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. / Stuart, N.S.; von Minckwitz, G.; Chernozemsky, I. et al.
Yn: Anti-Cancer Drugs, Cyfrol 16, Rhif 8, 01.09.2005, t. 871-877.

Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

TY - JOUR

T1 - Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

AU - Stuart, N.S.

AU - von Minckwitz, G.

AU - Chernozemsky, I.

AU - Sirakova, L.

AU - Chilingirov, P.

AU - Souchon, R.

AU - Marschner, N.

AU - Kleeberg, U.

AU - Tsekov, C.

AU - Fritze, D.

AU - Thomssen, C.F.

AU - Stuart, N.

AU - Vermorken, J.B.

AU - Loibl, S.

AU - Merkle, K.H.

AU - Kaufmann, M.

PY - 2005/9/1

Y1 - 2005/9/1

M3 - Article

SN - 0959-4973

VL - 16

SP - 871

EP - 877

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 8

ER -

Stuart NS, von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anti-Cancer Drugs. 2005 Medi 1;16(8):871-877.